EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Steady‐State Pharmacokinetic Properties of TNX‐102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open‐Label Trial

Gregory M Sullivan, Bernd Meibohm, Errol Gould, Bruce L Daugherty, Seth Lederman

Clinical Pharmacology in Drug Development · 2026-04 · 15 (4)

DOI: 10.1002/cpdd.70060 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 08.04.2026. Verfasst von Gregory M Sullivan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tonix Pharmaceuticals, Inc., Berkeley Heights, NJ, USA. Hauptthemen laut MEDLINE: Amitriptyline. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tonix Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This single‐center, open‐label, randomized, multiple‐dose, pharmacokinetic bridging study was conducted to compare systemic exposure (AUC and C max ) of a sublingual tablet formulation of cyclobenzaprine hydrochloride (TNX‐102 SL, approved as TONMYA) at steady‐state with that of an approved reference product, an oral, extended‐release (ER) capsule formulation, supporting development under the 505(b)(2) regulatory pathway. Healthy adults (N = 60) were randomly assigned 1:1 to receive two sublingual 2.8‐mg tablets or one oral ER 30‐mg capsule once daily for 20 days. At steady state, 2 sublingual 2.8 mg tablets provided lower exposure to cyclobenzaprine and norcyclobenzaprine compared with one oral 30‐mg ER capsule. However, when exposures were normalized by dose, cyclobenzaprine AUC 0‐24 and C max were higher on both Day 1 and Day 20 with two sublingual tablets versus one oral ER capsule, supporting higher bioavailability of the sublingual tablet formulation. For Day 20, the dose‐normalized ratios (two sublingual tablets: one oral ER capsule) for AUC 0‐τ ss and C max ss were 140% and 152%, respectively. Sublingual tablets and oral ER capsules had comparable metabolic profiles of Phase I and II metabolites in plasma over 20 days, with no unique metabolites by the sublingual route. Sublingual cyclobenzaprine HCl tablets were generally safe and well‐tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmitriptylineHumansAdultAdministration, SublingualMaleFemaleTabletsArea Under CurveYoung AdultMiddle AgedBiological AvailabilityHealthy VolunteersAdministration, OralDelayed-Action Preparations

Stichwörter der Autor:innen

cyclobenzaprinefibromyalgiasublingual

Substanzen

cyclobenzaprineTabletsAmitriptylineDelayed-Action Preparations

Autor:innen und Institutionen

  • Tonix Pharmaceuticals, Inc., Berkeley Heights, NJ, USA.
  • University of Tennessee Health Science Center, Memphis, TN, USA.
  • Tonix Medicines, Inc., Berkeley Heights, NJ, USA.

Förderung

  • Tonix Pharmaceuticals Inc

Zitieren

APA

Sullivan, G. M., Meibohm, B., Gould, E., Daugherty, B. L., & Lederman, S. (2026). Steady‐State Pharmacokinetic Properties of TNX‐102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open‐Label Trial. Clinical Pharmacology in Drug Development, 15(4). https://doi.org/10.1002/cpdd.70060

Vancouver

Sullivan GM, Meibohm B, Gould E, Daugherty BL, Lederman S. Steady‐State Pharmacokinetic Properties of TNX‐102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open‐Label Trial. Clinical Pharmacology in Drug Development. 2026;15(4). doi:10.1002/cpdd.70060

BibTeX
@article{Sullivan2026,
  author = {Sullivan, Gregory M and Meibohm, Bernd and Gould, Errol and Daugherty, Bruce L and Lederman, Seth},
  title = {Steady‐State Pharmacokinetic Properties of TNX‐102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open‐Label Trial},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cpdd.70060}
}
Kostenlos starten →